A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis

被引：11

作者：

Anolli, Maria Paola ^{[1
]}

Degasperi, Elisabetta ^{[1
]}

Allweiss, Lena ^{[2
,3
]}

Sangiovanni, Angelo ^{[1
]}

Maggioni, Marco ^{[4
]}

Scholtes, Caroline ^{[5
,6
,7
]}

Oberhardt, Valerie ^{[8
]}

Neumann-Haefelin, Christoph ^{[8
]}

Dandri, Maura ^{[2
,3
]}

Zoulim, Fabien ^{[5
,6
,7
]}

Lampertico, Pietro ^{[1
,9
,10
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[2] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, Hamburg, Germany

[3] German Ctr Infect Res DZIF, Hamburg Lubeck Borstel Riems Site, Hamburg, Germany

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Pathol Unit, Milan, Italy

[5] Hosp Civils Lyon HCL, Hepatol Dept, Lyon, France

[6] Univ Claude Bernard Lyon 1 UCBL1, Lyon, France

[7] Ctr Rech Canc Lyon CRCL, INSERM U1052, Lyon, France

[8] Univ Freiburg, Freiburg Univ Med Ctr, Fac Med, Dept Med 2, Freiburg, Germany

[9] Univ Milan, CRC AM&A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

[10] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Via F Sforza 35, I-20122 Milan, Italy

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷 / 04期

关键词：

Bulevirtide; HDV; HDV RNA; HBV; compensated cirrhosis; sustained virological response; clinically significant portal hypertension; liver fibrosis; HBcrAg; PBMC; HEPATITIS-D; MULTICENTER; EFFICACY; SAFETY;

D O I：

10.1016/j.jhep.2022.12.023

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Bulevirtide recently received conditional approval from the EMA for the treatment of chronic hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first case of hepatitis delta cure following 3 years of bulevirtide monotherapy in a patient with compensated cirrhosis and esophageal varices. During the 72-week off-bulevirtide follow-up, virological and biochemical responses were maintained. In the off-therapy liver biopsy, intrahepatic HDV RNA and hepatitis D antigen were undetectable, <1% of hepatocytes were hepatitis B surface antigen positive and all were negative for hepatitis B core antigen. Ishak grading and staging were improved following treatment.(c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

引用

页码：876 / 880

页数：5

共 50 条

[1] Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
Degasperi, Elisabetta
Anolli, Maria Paola
Renteria, Sara Colonia Uceda
Sambarino, Dana
Borghi, Marta
Perbellini, Riccardo
Scholtes, Caroline
Facchetti, Floriana
Loglio, Alessandro
Monico, Sara
Fraquelli, Mirella
Costantino, Andrea
Ceriotti, Ferruccio
Zoulim, Fabien
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2022, 77 (06) : 1525 - 1531
[2] Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis
Loglio, Alessandro
Ferenci, Peter
Renteria, Sara Colonia Uceda
Tham, Christine Y. L.
Scholtes, Caroline
Holzmann, Heidemarie
van Boemmel, Florian
Borghi, Marta
Perbellini, Riccardo
Rimondi, Alessandro
Farina, Elisa
Trombetta, Elena
Manunta, Maria
Porretti, Laura
Prati, Daniele
Ceriotti, Ferruccio
Zoulim, Fabien
Bertoletti, Antonio
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2022, 76 (02) : 464 - 469
[3] Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction
Masetti, Chiara
Aghemo, Alessio
LIVER INTERNATIONAL, 2021, 41 (07) : 1441 - 1442
[4] Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients
Loglio, Alessandro
Ferenci, Peter
Renteria, Sara Colonia Uceda
Tham, Christine Y. L.
van Boemmel, Florian
Borghi, Marta
Holzmann, Heidemarie
Perbellini, Riccardo
Trombetta, Elena
Giovanelli, Silvia
Greco, Letizia
Porretti, Laura
Prati, Daniele
Ceriotti, Ferruccio
Lunghi, Giovanna
Bertoletti, Antonio
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2019, 71 (04) : 834 - 839
[5] Bulevirtide monotherapy in patients with chronic HDV : Efficacy and safety results through week 96 from a phase III randomized trial
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Berger, Annemarie
Ciesek, Sandra
Manuilov, Dmitry
Mercier, Renee-Claude
Da, Ben L.
Chee, Grace M.
Li, Mingyang
Flaherty, John F.
Lau, Audrey H.
Osinusi, Anu
Wiesch, Julian Schulze zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2024, 81 (04) : 621 - 629
[6] Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide
El Messaoudi, Selma
Brichler, Segolene
Fougerou-Leurent, Claire
Gordien, Emmanuel
Gerber, Athenais
Kortebi, Amal
Lagadic, Garance
Subic-Levrero, Miroslava
Metivier, Sophie
Pol, Stanislas
Minello, Anne
Ratziu, Vlad
Leroy, Vincent
Mathurin, Philippe
Alric, Laurent
Coulibaly, Fatoumata
Pawlotsky, Jean-Michel
Zoulim, Fabien
de Ledinghen, Victor
Guedj, Jeremie
JHEP REPORTS, 2024, 6 (08)
[7] Equal 3-Year Outcomes for Kidney Transplantation Alone in HCV-Positive Patients With Cirrhosis
Parsikia, Afshin
Campos, Stalin
Khanmoradi, Kamran
Pang, John
Balasubramanian, Manjula
Zaki, Radi
Ortiz, Jorge
INTERNATIONAL SURGERY, 2015, 100 (01) : 142 - 154
[8] Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up
Chen, Wen-Bo
Shen, Xiao-Fei
Li, Qi
Zhou, Wen-Cheng
Cheng, Lei
IMMUNOTHERAPY, 2020, 12 (12) : 891 - 901
[9] High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort
Jan-Hendrik Bockmann
Marcel Grube
Vanessa Hamed
Johann von Felden
Johanna Landahl
Malte Wehmeyer
Katja Giersch
Michaela T. Hall
John M. Murray
Maura Dandri
Stefan Lüth
Ansgar W. Lohse
Marc Lütgehetmann
Julian Schulze Zur Wiesch
BMC Gastroenterology, 20
[10] High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort
Bockmann, Jan-Hendrik
Grube, Marcel
Hamed, Vanessa
von Felden, Johann
Landahl, Johanna
Wehmeyer, Malte
Giersch, Katja
Hall, Michaela T.
Murray, John M.
Dandri, Maura
Lueth, Stefan
Lohse, Ansgar W.
Luetgehetmann, Marc
Schulze Zur Wiesch, Julian
BMC GASTROENTEROLOGY, 2020, 20 (01)

← 1 2 3 4 5 →